Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

NCT06693531

Active Not RecruitingN/A

Sponsor: Regeneron Pharmaceuticals

Conditions: Eosinophilic Esophagitis (EoE)

Interventions: dupilumab

Countries: United States

This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure the following: * How EoE makes one feel * EoE signs and/or symptoms, eg, how difficult it is to swallow * How EoE affects quality-of-life * How EoE impacts aspects of daily life * How EoE symptoms have changed throughout the study

Eligibility overview

Sex: ALL

Age: 1 Year to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Key Inclusion Criteria:

1. Initiating treatment with DUPIXENT® for EoE according to the USPI
2. Participants aged ≥12 years and caregivers or legal guardians of participants aged \<12 years must be able to understand and complete registry-related questionnaires

Key Exclusion Criteria:

1. Patients who have a contraindication to DUPIXENT® according to the USPI
2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment
3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator)

NOTE: Other protocol defined inclusion/exclusion criteria apply
Locations (54)
  • Phoenix, Arizona, United States
  • Sun City, Arizona, United States
  • Little Rock, Arkansas, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • Los Angeles, California, United States
  • Oakland, California, United States
  • Palo Alto, California, United States
  • San Francisco, California, United States
  • Aurora, Colorado, United States
  • Aurora, Colorado, United States
  • Littleton, Colorado, United States
  • Farmington, Connecticut, United States
  • New Haven, Connecticut, United States
  • Orange City, Florida, United States
  • Orlando, Florida, United States
  • Atlanta, Georgia, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Chicago, Illinois, United States
  • Libertyville, Illinois, United States
  • Skokie, Illinois, United States
  • Wichita, Kansas, United States
  • Owensboro, Kentucky, United States
  • Boston, Massachusetts, United States
  • Boston, Massachusetts, United States
  • Boston, Massachusetts, United States
  • Rochester, Minnesota, United States
  • Flowood, Mississippi, United States
  • Kansas City, Missouri, United States
  • + 24 more on CT.gov